Arrhythmogenic Activity During Exercise in ARVC Patients

Inclusion Criteria: * Definitive ARVC diagnosis according to the modified 2010 ARVC Task Force Criteria * Pathogenic / likely pathogenic variant in one of the following desmosomal genes: plakophilin-2 (PKP-2), desmoglein-2 (DSG-2) or desmoplakin (DSP) or gene-elusive definite ARVC (i.e., genetic test performed but no pathogenic / likely pathogenic variant found) * Agreement with responsible primary cardiologist that study participation is not considered beyond acceptable levels of physical activity for this particular patient * No history of exercise-induced syncope in the 6 months prior to study participation * No history of sudden cardiac arrest in the 6 months prior to study participation * In patients who suffered from sudden cardiac arrest/arrhythmic syncope, only those having an implantable cardioverter-defibrillator (ICD) and being under beta-blockers/antiarrhythmic drugs are eligible for study inclusion * Informed Consent as documented by signature (Appendix Informed Consent Form) * Age: \> 18 years * Body-Mass-Index (BMI): 18.5 - 29.9 kg･m-2 * Willing to adhere to the following study rules: * No intense exercise 48h prior to testing * No exercise 24h prior to testing * Sleep at least 7h the two nights before testing On test day * No caffeinated food or drink before testing on test day * No alcohol before testing on test day * Fully compliant with normal medication regimen including beta-blockers and antiarrhythmic medication Exclusion Criteria: * No genetic test history for ARVC variants * Heart failure with severely reduced left ventricular ejection fraction (LVEF \<35%) * For women: Pregnancy, breastfeeding, or intention to become pregnant during the study. * Known or suspected non-compliance, drug, or alcohol abuse * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant * Previous enrolment into the current study